Tag
Concise review of the 2025 VA/DoD lipid guideline: new risk tool (PREVENT), CAC and one-time Lp(a) for risk refinement, statins for selected primary prevention groups (including people with HIV), and intensified combination therapy for very
This review synthesizes evidence linking aspirin use to reduced risk of calcific aortic valve disease in persons with elevated lipoprotein(a), highlighting the potential for targeted preventive strategies.
Lepodisiran, an siRNA targeting Lp(a), significantly reduces oxidized phospholipids on apo(a) and apoB, highlighting its therapeutic potential in lowering cardiovascular risk linked to elevated Lp(a).
Elevated lipoprotein(a) confers a consistent relative risk increase for atherosclerotic cardiovascular disease across all adult ages, with absolute risks rising substantially in older adults.
A cohort study demonstrates increased major cardiovascular event risk in first-degree relatives of individuals with high plasma lipoprotein(a), supporting cascade screening for targeted prevention.
Risk-weighted apoB (RW-apoB) integrates LDL, TRL/remnants, and Lp(a) atherogenicity to improve coronary heart disease risk prediction, outperforming conventional lipid biomarkers like apoB and LDL-C in multiple population cohorts including
Obicetrapib significantly lowers lipoprotein(a), LDL cholesterol, and apolipoprotein B in high cardiovascular risk patients, offering a promising addition to lipid-lowering therapies, especially for patients with mild to moderate Lp(a) elev
Elevated lipoprotein(a) increases coronary artery disease risk, but this study reveals that inflammation—particularly IL-6 levels—modulates this risk, highlighting the importance of inflammatory biomarkers in cardiovascular risk assessment
In VESALIUS-CV, elevated baseline Lp(a) independently predicted major coronary events, especially MI, in patients without prior MI or stroke. Evolocumab reduced relative risk similarly across Lp(a) levels, with numerically greater absolute
A large-scale multicohort study demonstrates that while elevated Lipoprotein(a) increases cardiovascular risk, Coronary Artery Calcium (CAC) scoring remains a powerful independent predictor of events, even in patients with high Lp(a) levels
A large multicohort study involving 11,319 participants confirms that Coronary Artery Calcium (CAC) scoring effectively stratifies cardiovascular risk even in individuals with high Lipoprotein(a), providing clinical clarity for personalized
Longitudinal data from the Women’s Health Study reveal that elevated Lipoprotein(a) is a potent, independent predictor of myocardial infarction and ischemic stroke over three decades, suggesting a critical need for universal screening in pr
This evidence-based analysis of the EXCELSIOR trial explores the relationship between OxPL-apoB, platelet activation, and long-term outcomes, finding that while these phospholipids predict major cardiovascular events, they do not appear to
A secondary analysis of the ODYSSEY OUTCOMES trial reveals that oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) independently predict cardiovascular risk in ACS patients, particularly when Lp(a) levels are low. Treatment with ali
This review synthesizes evidence on the performance of AHA PREVENT equations in individuals with elevated lipoprotein(a), emphasizing its independent risk association and potential to enhance personalized ASCVD risk prediction.
In 273,770 US patients with established ASCVD, rising lipoprotein(a) (nmol/L) was steadily associated with higher risk of recurrent events; the excess risk was partially blunted in those receiving high‑impact LDL‑lowering therapy, most nota
A pooled analysis of three large cohorts found no consistent association between circulating lipoprotein(a) and Alzheimer’s disease or vascular dementia, but genetic evidence for very small apo(a) isoforms suggests a modest increase in Alzh
A 30-year prospective study reveals that elevated hsCRP, LDL cholesterol, and lipoprotein(a) levels independently and collectively increase the risk of ischaemic stroke in healthy women, advocating for early biomarker screening in stroke pr
Elevated lipoprotein(a) levels significantly predict incident peripheral artery disease and carotid stenosis, as well as progression to major limb events, underscoring its value as a prognostic biomarker for extracoronary atherosclerotic va
A landmark UK Biobank study demonstrates that elevated lipoprotein(a) independently predicts both the onset and progression of peripheral artery disease and carotid stenosis, beyond traditional cardiovascular risk factors.
